Objective: This study documents our experience with a new 9 French (FR) 8 mm cryocatheter for ablation treatment of symptomatic atrial flutter.
Introduction
Radio frequency (RF) ablation of the isthmus between the tricuspid annulus and the inferior vena cava is commonly used to treat atrial flutter [1] . This well-established target is known as the cavotricuspid isthmus (CTI) [2, 3] . This target can also be successfully ablated by delivering cryoenergy to it using a hand held catheter [4] [5] [6] . The feasibility of this approach was first demonstrated by Dubuc and colleagues in a series of experiments in dogs [7] , and more recently there has been an accumulation of clinical experience with cryoablation catheters in the treatment of patients with both common and atypical atrial flutter [8] [9] [10] [11] .
Our experience, as well as that of others, is that the focal lesions produced by cryoablation are effective in creating permanent bidirectional isthmus block [8] [9] [10] . Recent use of a 7 French 6 mm tip cryocatheter to treat atrial flutter in 98 patients showed our ablation technique to be feasible, safe, and capable of producing a high rate of acute success at intervention, i.e., bidirectional block was maintained in 86% of patients upon retesting, performed 30 min after initial block was recorded [10] . Nonetheless, our practical experience has led us to propose that a larger tipped catheter, capable of producing wider and deeper cryolesions, might deliver even further benefits. A larger tipped catheter is expected to be an effective and powerful alternative while maintaining the general benefits of cryo-ablation, which include preservation of the underlying tissue architecture and minimal thrombus formation [12, 13] .
Recurrence rates following RF ablation treatment for atrial flutter are from 0 to 31% over follow-up periods ranging from 6 to 68 months [11, [14] [15] [16] . The wide variation in recurrence rates reported by these studies may be due in part to different methods of recording recurrence-some studies have documented recurrence primarily by ECG and/or patient diary records whereas others have performed invasive repeat EPS post ablation. A recent study involving cryoablation treatment for atrial flutter reported a symptom recurrence rate of 11% over a mean follow-up period of approximately 18 months [8] . Although this study demonstrated the long-term efficacy of cryoablation treatment for atrial flutter, the method of recording recurrence did not involve a repeat EPS, and consequently some patients categorized as asymptomatic may have had conduction recurrence demonstrated with repeat EPS. Such patients are a potential reservoir of individuals who could eventually experience symptoms of atrial flutter.
The aim of this study was to document our experience with a new 9 French, 8 mm tip, quadripolar cryocatheter in the treatment of patients with atrial flutter. Apart from safety and acute efficacy data we sought to assess long-term efficacy by performing a follow-up assessment of arrhythmia recurrence using repeat EPS as well as ECG and patient diary records.
Method Patient Population and Study Design
The study population consisted of 77 consecutive patients with symptomatic atrial flutter who were referred to our institute to undergo ablation for recurrent atrial flutter between May 2003 and March 2004. The local ethics committee approved the protocol and informed consent was obtained from all patients prior to the procedure. All patients had previously been treated for atrial flutter with two or more drug regimens at the time of the ablation. Eligibility for ablation required that all patients had at least two documented symptomatic episodes of atrial flutter recorded either by ECG or Holter monitoring. All patients received an echocardiogram to ascertain the existence of cardiac pathology, underlying cardiac disease, and to measure left ventricular ejection fraction (LVEF). Anti-arrhythmic drugs were withdrawn in all patients at least one week prior to ablation, with the exception of amiodarone that was withdrawn 8 weeks prior to intervention; only five patients were on amiodarone preablation. The anti-anxiety drug diazepam was administered to a few patients at the discretion of the investigator. Patients were not administered anticoagulants as part of the ablation procedure. Three month follow-up data was available from 47 patients, all of whom were successfully ablated at intervention.
Endpoints

Bidirectional conduction block at intervention
was assessed by:
(a) pacing the atrium at the CS immediately adjacent to the line of block (e.g., CS os) and recording at the lateral free wall (AL1). If the resultant atrial activation on the opposite side of the line of block at AL1 is late, it indicated that the wave of depolarization must proceed around the entire right atrium in a counter-clockwise direction to the opposite side of the line of block. (b) pacing from AL1 on the lateral free wall and recording at the CS os. This confirmed that the resultant atrial activation at the CS os is late, indicating that the wave of depolarization must proceed around the entire right atrium in a clockwise direction to the opposite side of the line of block.
2. At three month follow-up, a repeat EPS was performed to determine whether conduction recurrence could be demonstrated. Atrial flutter inducibility and bidirectional conduction were evaluated. The programmed atrial stimulation involved a basic drive cycle length of 600 ms and a single extrastimulus at 400 msec with 20 ms decrements. If this was ineffective, a second cextrastimulus at 300 ms with 20 ms decrements was delivered. 3. Recurrence rate at 6 months post procedure as documented by ECG and/or patient diary records. 4. Adverse events and patient reporting of discomfort with cryoenergy delivery were recorded.
Electrophysiologic Techniques
A 7 French, 24-pole catheter (Orbiter, USCI-Bard Inc., Bellerica, USA) with alternating 2-14-2 mm inter-electrode distance was placed, via the right femoral vein, into the trabeculated right atrium to simultaneously record electrical activity in the right atrial free wall, the atrial roof, and the anterior septum. A 10-pole catheter (USCI-Bard Inc., Bellerica, USA) was placed in the CS via the left subclavian vein for recording the left atrium and part of the infero-posterior atrial septum. A 10-pole catheter with 2 mm inter-electrode spacing was inserted via the right femoral vein and positioned along the atrial septum in the His bundle region.
Ablation
In all cases, a commercially available 9 French deflectable, quadripolar catheter with an 8 mm tip electrode (Freezor R MAX, CryoCath Technologies Inc., Kirkland, Canada) available with a large reach was used. Cooling of the catheter is facilitated through delivery of nitrous oxide (N 2 O) to the tip, whereupon a phase change from liquid to gas occurs with a subsequent temperature reduction to approximately −75
• C at the isthmus. The cryocatheter is connected to a console via an electrical cable and gas umbilical tube. The gas umbilical provides a lumen for the warmed, vaporized N 2 O to be returned to the cryoconsole under constant vacuum, whereas the electrical umbilical wire allows intracardiac electrograms to be recorded from the Lab System and safety functions to be displayed on the console. Bipolar intracardiac electrograms filtered between 30 and 250 Hz were digitally recorded and stored on a Lab System 3.57 (USCI-Bard Inc., Bellerica, USA). A 3-lead surface ECG was used simultaneously. Digital calipers were used to calculate atrial activation times in sinus rhythm and the atrial flutter cycle length (F-F intervals).
Baseline Electrophysiological Study (EPS)
A baseline EPS was performed on all the patients to exclude other electrophysiological disorders that could be responsible for their episodes of atrial flutter. This EPS was performed on all the patients in sinus rhythm and in a non-sedated state. All the patients received local anesthesia with lidocaine. Pacing was delivered via the orbiter catheter placed close to the right atrial auricula at twice the diastolic threshold with a 2 ms pulse width. During the baseline EPS, sustained or non-sustained atrial flutter was induced by programmed atrial stimulation in order to identify patterns of activation consistent with a typical form of atrial flutter or rapid atrial tachycardia. It was possible to induce atrial flutter in approximately 90% of our patient group. Some patients received isoproterenol preablation to promote induction of atrial flutter. Thereafter, atrial, pacing at a cycle length 20% shorter than the atrial flutter cycle length, was used to perform concealed entrainment and terminate atrial flutter. In the remaining 10% of patients where atrial flutter could not be induced, we moved directly to isthmus site evaluation and subsequent ablation.
Catheter Position and Ablation Protocol
In all the procedures, anatomical markers under fluoroscopic guidance (45
• LAO and RAO projections) were used to place the catheter in the desired position (Fig. 1) . The ablation catheter was positioned to ensure stability plus good electrodeendocardium contact. This was confirmed by stable intracardiac electrograms. Cryothermal testing, which involved delivery of cryoenergy for up to 60 s to create transient reversible conduction block, was then performed in order to identify the target site for successful ablation of the arrhythmia. Successful cryothermal testing at a target site would cause prolongation of conduction for 30 to 40 s. If prolongation of conduction was not achieved then cryoenergy delivery was halted, the target tissue was allowed to rewarm and regain its electrophysiological properties and the catheter was repositioned to a new target site where the cryotest was repeated. This ability to create transient reversible conduction block using cryoenergy has been discussed elsewhere under the guise of cryothermal or ice mapping [17] . When cryotesting caused the desired conduction block (e.g., complete bidirectional block of conduction over the CTI) then by maintaining delivery of cryoenergy for 8 min at −75
• C a permanent cryolesion was formed. Cryoenergy was applied for 8 min based on the investigator's experience with previous WPW and AVNRT cryoablations that showed significant prevalence of conduction recurrence when only 4 min cryoapplications were delivered at −75
• C. A longer period of exposure to cryoenergy was expected to be more effective. Cryothermal applications were delivered during atrial flutter with the flutter terminating during the ablation; complete isthmus block was necessary as interruption per se did not mean successful ablation. Double potentials across the atrial flutter line were demonstrated during the ablation (Fig. 2) . Bidirectional conduction block defined the endpoint of the ablation procedure (Fig. 3) . Assessment of whether bidirectional block was achieved was by pacing the atrium from the CS os and sensing on the lateral wall, and vice-versa as described earlier i.e., pre and post ablation protocols were identical. The current levels that were used to capture at this location were 15 mA amplitude and 5 ms duration. Once bidirectional block was achieved, no additional cryo-applications were made to complete a lesion line across the CTI. A 30 min wait period occurred between the initial successful ablation and subsequent re-testing to ensure that the bidirectional block remained. Patients were asked to report any discomfort they felt throughout the ablation procedure; their comments were recorded on a patient chart.
Fig. 1. Fluorographic images of anatomical placement of the new 9 French, 8 mm tip, quadripolar cryocatheter for treatment of atrial flutter. (Cryoablation catheter (ABl), anterolateral right atrial wall electrode (AL1), distal coronary sinus electrode (CS1), proximal electrode at coronary sinus os (CS os), HIS bundle catheter (HIS), left anterior oblique (LAO), midseptal electrode (MS12), and right anterior oblique (RAO)).
and 6 Month Follow-Up
All patients kept a diary record of symptoms experienced following the ablation procedure. These records were collected at our out-patient clinic every month. A general cardiovascular check-up and ECG were also performed as part of the clinical follow-up. A follow-up invasive repeat EPS was performed on all consenting patients at approximately 3 months post ablation.
Statistical Analysis
A Fisher's Exact
Test was used to analyze acute success data within contingency tables. STATIS-TICA version 6.0 (StatSoft Inc., USA) was used for all statistical analysis. The significance level was set at P < 0.05.
Results
Demographics
The study population consisted of 77 patients with symptomatic atrial flutter. The mean ± SD age and arrhythmia duration were 59.7 ± 12.6 years and 41.9 ± 39.2 months, respectively. Seven (11%) patients had a LVEF ≤ 35%, 23 (30%) patients had hypertension, 1 (1%) patient had primary dilated cardiomyopathy, 4 (5%) patients had a coronary artery bypass graft, and 9 (12%) patients had cardiac heart disease.
Safety: Acute and Follow-Up Data
There were no reported adverse events during or post ablation procedure prior to discharge from hospital. There was no incidence of cryothermia induced permanent AV block. None (0%) of the 77 patients experienced discomfort on cryoenergy delivery.
No adverse events were reported in any patient between hospital discharge and 6 month followup, or at the repeat EPS.
Efficacy: Acute and Follow-Up Data
The overall acute success rate associated with this catheter was 96%. Acute success was achieved in 66 (100%) of 66 patients with common atrial flutter and 8 (73%) of 11 patients with atypical atrial flutter. Acute success was significantly higher for ablation of common atrial flutter than atypical atrial flutter (P = 0.002; Fishers Exact Test).
Three month repeat EPS data was available from 47 acutely successful patients (Table 1) . Conduction recurrence was demonstrated in 14 (30%) of 47 patients, although not in 33 (70%) of 47 patients. Only 1 (2%) of 47 patients had both symptom and conduction recurrence.
At 6 month follow-up, data available from 53 acutely successful patients showed that 48 (91%) were asymptomatic and 5 (9%) had experienced recurrence documented either by ECG and/or patient diary records. Each patient with documented symptoms by patient diary also had an ECG demonstration of recurrence.
Procedure Characteristics
Fluorographic images of anatomical placement of the 9 French, 8 mm tip, quadripolar cryoablation catheter (Fig. 1) , demonstration of double potentials across the atrial flutter line during the ablation procedure (Fig. 2) , and intracardiac electrograms pre and post bidirectional conduction 
Fig. 3. Intracardiac electrograms showing pre and post bidirectional conduction block before, during, and after cryoablation. The first tracing shows pacing from the CS resulting in two wavefronts of activation that collide on AR4, the roof of the right atrium. Subsequent tracings show progressive conduction block over the isthmus resulting in a single activation front from the CS os to AL1. (Cryoablation catheter proximal (ABL P) and distal (ABL D), anterolateral right atrial wall electrode (AL1), distal coronary sinus electrode (CS1), proximal electrode at coronary sinus os (CS os), HIS bundle catheter (HIS), and midseptal electrode (MS 12)).
block before, during, and after cryothermal ablation (Fig. 3) are shown. The mean ± SD number of cryotests and ablations performed for all 77 patients was 21 ± 20 (range: 0-118) and 4 ± 4 (range: 0-17), respectively. The average number of cryotests and ablations for particular groups of patients are shown ( Table 2 ). The mean ± SD procedure time and fluoroscopy time for all 77 patients was 38 ± 28 min (range: 8-215) and 16 ± 11 min (range: 4-63), respectively. The characteristics associated with patients who were (n = 13) and were not (n = 34) demonstrated to have conduction recurrence on repeat EPS are provided (Table 3) .
Discussion
Cryothermal ablation has been shown to offer a number of advantages over other energy sources in terms of safety and absence of discomfort [10, 11, 18] . Similarly, no adverse events or patient discomfort with cryoenergy delivery were reported in the present study. This reflects an excellent safety profile for this new 9 French 8 mm catheter. In contrast, pain has been reported to be experienced by patients with atrial flutter who were treated with RF ablation [18] , possibly because the ablation site is highly innervated and close to the CS os. The use of cryothermal energy allowed ablation around the CS os without causing pain in patients receiving only mild sedation. At intervention, bidirectional conduction block was created in 66 (100%) patients with common atrial flutter and 8 (73%) patients with atypical atrial flutter. However, 3 month follow-up data showed that although 46 (98%) of 47 patients were asymptomatic, conduction recurrence was demonstrated in 14 (30%) of 47 patients on repeat EPS. Nonetheless, only 1 (2%) patient experienced both symptom and conduction recurrence. Six month followup data showed that 48 (91%) of 53 acutely successful patients were asymptomatic and 5 (9%) of 53 acutely successful patients had experienced recurrence documented either by ECG and/or patient diary records. Although 6 month data demonstrate the long-term efficacy of cryothermal ablation when assessed in terms of symptom recurrence, 3 month repeat EPS data suggest that there is potentially a reservoir of asymptomatic patients who may eventually become symptomatic.
As previously found with a smaller 7 French 6 mm tipped catheter [9, 10] , acute success was significantly higher for ablation of common than atypical atrial flutter (P = 0.002; Fishers Exact Test). Because critical areas of the isthmus may originate in the left atrium or upper right atrium, even though the activation pattern in the right atrium mimics that of common right atrial flutter, atypical atrial flutter may be more difficult to ablate. The three (4%) patients who did not experience acute success had atypical atrial flutter. The unsuccessful outcome in these patients was primarily due to failure in localizing a target site for ablation. Indeed, two of the three acute failures did not receive a single ablation although a number of cryothermal tests were performed. The number of cryothermal tests performed was not markedly different between the three acute failures and the 74 acute successes (Table 2) . However, patients with atypical atrial flutter tended to have more cryothermal tests and greater incidence of subsequent failure of ablation to create bidirectional block at the same site compared to patients with common atrial flutter. Data concerning how many times a specific cryothermal test succeeded but subsequent ablation at the same site failed to create bidirectional block was not captured in this study; only data relating to the total number of cryothermal tests and ablations was captured for each patient. Analysis of various electrophysiological and ablation characteristics associated with patients who were or were not recurrent on repeat EPS failed to identify any strong predictors of conduction recurrence (Table 3) . On average, more cryothermal tests were performed with the new 9 French 8 mm catheter than has been reported for a smaller 7 French 6 mm tipped cryothermia catheter, although the number of ablations were much less [9, 10] . The former may be due to a combination of altered mapping resolution of the catheter and/or a disproportionately large number of cryothermia tests being performed in a few complex cases. An example of the latter is a patient with atypical atrial flutter who underwent 118 cryothermia tests. A total of four ablations were performed on this patient, who ultimately was an acute success and did not have conduction recurrence on repeat EPS at 3 month follow-up. This patient had previously been treated with RF ablation for the same arrhythmia, so the presence of scar tissue around the site for ablation may have accounted for the excessive number of cryothermia tests that were needed. Indeed, the average number of cryothermia tests performed on the four patients with previous RF ablation was greater than for those patients who did not have previous RF ablation ( Table 2 ). The fewer number of cryoablations required with the larger-tipped catheter compared with smaller-tipped catheters suggests a greater ability to create deeper and wider lesions with the former. Preclinical studies comparing lesion sizes created by catheters of various tip size would help verify this.
The proof of bidirectional conduction block in the CTI remains a critical issue in the confirmation of a successfully ablated atrial flutter. The performance of electro-anatomical mapping would have been useful to clearly demonstrate conduction across the ablation line. Although, the literature reports unidirectional or rate dependent conduction block in more than 31% of the patient population treated with RF ablation [3, 19] , this was not our experience with cryothermia. This suggests two possibilities. First, the area where we created lesions was more critical compared with the standard conventional isthmus lesion [10] . Second, cryoenergy produces a lesion more likely to result in bidirectional block. Each of these possibilities requires further investigation. Despite nearly all patients (74 of 77 patients) being demonstrated to have bidirectional block at the 30 min retest proceeding the initial creation of conduction block at intervention, conduction recurrence was demonstrated in a number of asymptomatic patients consenting to repeat EPS at three months. The ablation technique performed at intervention may explain why a number of these asymptomatic patients were found to have conduction recurrence-the technique may have potentially left an anterior gap as the ablation started relatively posteriorly in the isthmus below the CS ostium. Ultimately, this investigation raises the issue that clinical recurrence of atrial flutter may not be totally dependent on complete conduction block across the isthmus. However, since the conclusion derived from post ablation assessment is dependent on location of the diagnostic catheters, it would have been useful to utilize specific markers to completely ensure that pre and post ablation conduction results were not in any way possibly due to differences in catheter location at each recording period.
The mapping characteristics of the 11 patients with atypical atrial flutter showed particular features. Those unsuccessful atypical atrial flutter patients did not share the same isthmus characteristics as those patients with common atrial flutter-they exhibited upper loop atrial flutter and left atrial flutter even though they had similar ECG morphology and atrial activation. Successful atypical atrial flutter patients exhibited dual loop atrial flutter and shared the common isthmus. Use of 3D mapping as part of the cryoablation procedure would have been useful in further elucidating the characteristics of patients with atypical atrial flutter.
Limitations of the Study
This study has limitations. First, this study was not controlled. It was a single arm study with no randomized comparison to other smaller tipped cryothermal ablation catheters or RF ablation catheters. Nonetheless, this study ultimately sought to document our experience with a new 9 French, 8 mm cryothermal ablation catheter for treatment of patients with symptomatic atrial flutter. Second, this study involved only 77 patients. However, the study population had 86% of patients with common atrial flutter. Therefore, the 77 patients that were treated were representative of the general population of symptomatic patients commonly referred to expert centers for ablation of atrial flutter. Third, an anatomical approach to ablation was used. This may have particularly compromised the ablation procedure in the three acute failures who had atypical atrial flutter. This approach may be improved by looking for a specific electrogram to help identify a suitable site for ablation. Fourth, use of stable intracardiac electrograms to indicate catheter stability plus good electrode-endocardium contact may have been inappropriate. The use of stable pacing capture with low capture current may have been a better alternative. Fifth, the recurrence rate was assessed by patient symptoms and not in a definitive manner such as with an event recorder that could clearly identify arrhythmia. Hence, the data regarding the recurrence rate may not precisely reflect the failure rate. Despite this limitation, all symptomatic patients clearly exhibited symptoms and patients were able to identify their symptoms with ease. Moreover, patients underwent a monthly Holter recording to identify possible asymptomatic recurrences. Finally, three month follow-up data was available from only 47 patients, all of whom experienced acute success with cryothermia. In a number of these patients, repeat EPS demonstrated conduction recurrence even though these patients were asymptomatic. Although this disparity may allude to the possibility of there being a critical area for ablation to eradicate symptomatic atrial flutter, alternatively these asymptomatic patients who had conduction recurrence may ultimately be a reservoir of patients who will eventually experience symptom recurrence. Indeed, the symptom recurrence rate increased from 2% at three month follow-up to 9% at six month follow-up. Extended follow-up would be useful to determine whether the symptom recurrence rate documented by ECG and/or patient diary records eventually equals the conduction recurrence rate identified by repeat EPS at three months post ablation.
Conclusion
This study documents our experience with a new 9 French 8 mm catheter for cryothermal ablation treatment of symptomatic atrial flutter. Neither adverse events nor discomfort with cryoenergy delivery were reported with the use of this catheter. Acute success, defined as bidirectional isthmus block at intervention, was achieved in 96% of treated patients; it was 100% for those patients with common atrial flutter. Three month follow-up data available from 47 acutely successful patients showed that 46 (98%) patients were asymptomatic. Although, conduction recurrence was demonstrated in 14 (30%) patients on repeat EPS at three months, only 1 (2%) patient had both symptom and conduction recurrence. Data available from 53 acutely successful patients at six month clinical follow-up showed that 48 (91%) patients were asymptomatic and 5 (9%) patients had recurrence documented by ECG and/or patient diary records. Altogether, these results demonstrate that the new 9 French, 8 mm tip, quadripolar cryothermal ablation catheter has a high acute success rate and an excellent safety profile. Further monitoring is necessary to assess whether the relatively low recurrence rate observed at six month clinical follow-up is maintained over a long term.
